D
David A. Cooper
Researcher at Pfizer
Publications - 965
Citations - 81765
David A. Cooper is an academic researcher from Pfizer. The author has contributed to research in topics: Acquired immunodeficiency syndrome (AIDS) & Viral load. The author has an hindex of 117, co-authored 903 publications receiving 69249 citations. Previous affiliations of David A. Cooper include Boston Children's Hospital & National Institutes of Health.
Papers
More filters
Journal ArticleDOI
Prehospital rapid sequence intubation improves functional outcome for patients with severe traumatic brain injury: A randomized controlled trial
Stephen Bernard,Vina Nguyen,Peter Cameron,Kevin Masci,Mark Fitzgerald,David A. Cooper,Tony Walker,B Paramed Std,Paul S. Myles,Lynne Murray,David,Taylor,Karen Smith,Ian Patrick,John Edington,Andrew Bacon,Jeffrey V. Rosenfeld,Rodney Judson +17 more
TL;DR: In adults with severe TBI, prehospital rapid sequence intubation by paramedics increases the rate of favorable neurologic outcome at 6 months compared with intubations in the hospital.
Journal ArticleDOI
Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials
Charles B. Hicks,Pedro Cahn,David A. Cooper,Sharon Walmsley,Christine Katlama,Bonaventura Clotet,Adriano Lazzarin,Margaret Johnson,Dietmar Neubacher,Douglas L. Mayers,Hernan Valdez +10 more
TL;DR: In this article, the authors compared the efficacy and safety of the novel non-peptidic protease inhibitor tipranavir co-administered with ritonavir plus an optimised background regimen with that of an investigator-selected Ritonavirus-boosted comparator protease inhibitors (CPI-ritonavir) in such patients.
Journal ArticleDOI
Primary HIV infection: host responses and intervention strategies.
Brett Tindall,David A. Cooper +1 more
TL;DR: In this review, the concepts that have emerged regarding primary HIV infection are summarized and the possibility of chemotherapeutic intervention is discussed.
Abacavir Substitution for Nucleoside Analogs in Patients With HIV Lipoatrophy
TL;DR: In this sample of lipoatrophic HIV-infected adults, switching from stavudine or zidovudine to abacavir for 24 weeks led to significant, albeit modest, objectively measured increases in limb fat, and clinical lipoatrophy, as assessed subjectively, did not resolve.
Journal ArticleDOI
Viral suppression and HIV transmission in serodiscordant male couples: an international, prospective, observational, cohort study
Benjamin R Bavinton,Angie N Pinto,Nittaya Phanuphak,Beatriz Grinsztejn,Garrett Prestage,Iryna Zablotska-Manos,Fengyi Jin,Christopher K Fairley,Richard James Moore,Norman Roth,Mark Bloch,Catherine Pell,Anna McNulty,David Baker,Jennifer F Hoy,B K Tee,David J Templeton,David A. Cooper,Sean Emery,Anthony D. Kelleher,Andrew E. Grulich +20 more
TL;DR: Transmission rates in couples reporting condomless anal intercourse are calculated, when HIV-positive partners were virally suppressed, and daily pre-exposure prophylaxis (PrEP) was not used by HIV-negative partners.